MORE ADHD IN THE NEWS THIS WEEK. We found these items:
- A Canadian pharmaceutical company has announced postive clinical trials for an ADHD drug product called Benjorna. While the drug is methylphenidate-based, the delivery platform is apparently new, involving once-a-day dosage at bedtime. An industry newsletter says, "Benjorna demonstrated improved ADHD functioning during the morning routine and patients continued to show a robust clinical effect at 8 p.m. the following day – 24 hours after dosing – with no meaningful increase in sleep-related side effects." Read more.
- A new study performed on mice indicates that high doses of amphetamines, one of the two types of stimulant meds used to treat ADHD, could have long-term effects on the brain. The study write-up did not define "high doses" in a way that relates to human consumption. Read more.
- U.S. pediatricians very widely in the proportion of children they diagnose with ADHD. Across practices, the rate of diagnosis can range from 1 percent to 16 percent. Read more.
ANXIETY. An article at the site of the Child Mind Institute says that in terms of medicines to treat anxiety in kids, "antidepressants trump all others as the most effective evidence-based choice." Find the article. Separately, a University of Hawaii psychologist reviewed 50 years of research on treating childhood anxiety. According to a write-up, the study found that "among the six treatments, cognitive behavioral therapy (CBT) is most studied and is an appropriate first line treatment for youth with anxiety disorders." Find the write-up.
AND FINALLY, THIS. Jen the Blogger mixes her metaphors in a posting on parenting gifted and 2e teens. Find her musings.